Targeting RANK signaling to improve bone health in multiple myeloma patients
RANK Signaling Inhibitors for Osteolytic Lesions in Multiple Myeloma
['FUNDING_R21'] · UNIVERSITY OF ALABAMA AT BIRMINGHAM · NIH-11033229
This study is looking at new medications that could help reduce bone damage in people with multiple myeloma by targeting specific pathways in the body, aiming to find safer options than current treatments.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ALABAMA AT BIRMINGHAM (nih funded) |
| Locations | 1 site (BIRMINGHAM, UNITED STATES) |
| Trial ID | NIH-11033229 on ClinicalTrials.gov |
What this research studies
This research investigates new small molecule inhibitors that target RANK signaling pathways to reduce bone lesions in patients with multiple myeloma. By focusing on the mechanisms that lead to osteoclast formation, the study aims to develop treatments that minimize the risk of serious side effects associated with current therapies like denosumab and bisphosphonates. The approach involves both in vitro and in vivo studies to understand how these inhibitors can effectively reduce bone damage without compromising immune function. Patients may be involved in trials to assess the safety and efficacy of these new treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with multiple myeloma who are experiencing bone lesions or related skeletal complications.
Not a fit: Patients who do not have multiple myeloma or those without bone lesions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective treatments for bone lesions in multiple myeloma patients, improving their quality of life.
How similar studies have performed: Previous research has shown promise in targeting RANK signaling pathways, but this specific approach using small molecules is novel and untested.
Where this research is happening
BIRMINGHAM, UNITED STATES
- UNIVERSITY OF ALABAMA AT BIRMINGHAM — BIRMINGHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FENG, XU — UNIVERSITY OF ALABAMA AT BIRMINGHAM
- Study coordinator: FENG, XU
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.